Astria Therapeutics (NASDAQ:ATXS) Stock Passes Above Fifty Day Moving Average – Should You Sell?

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s stock price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $7.99 and traded as high as $12.38. Astria Therapeutics shares last traded at $12.38, with a volume of 1,429,504 shares changing hands.

Analysts Set New Price Targets

ATXS has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $49.00 price target on shares of Astria Therapeutics in a research note on Wednesday, September 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Astria Therapeutics in a research note on Wednesday, October 8th. Oppenheimer downgraded shares of Astria Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 14th. HC Wainwright lowered shares of Astria Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 16th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. Three investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $25.00.

Astria Therapeutics Stock Up 1.4%

The stock has a market capitalization of $698.73 million, a PE ratio of -6.16 and a beta of 0.43. The firm’s fifty day moving average price is $7.99 and its two-hundred day moving average price is $6.28.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.04. As a group, analysts predict that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Institutional Trading of Astria Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in Astria Therapeutics by 185.8% in the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,557 shares during the period. Brooklyn Investment Group increased its position in shares of Astria Therapeutics by 1,079.6% during the 1st quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 7,957 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Astria Therapeutics by 1,127.4% in the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 7,971 shares during the period. Corton Capital Inc. bought a new position in shares of Astria Therapeutics in the 1st quarter worth approximately $72,000. Finally, AlphaQuest LLC boosted its holdings in shares of Astria Therapeutics by 100.9% in the first quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company’s stock worth $76,000 after buying an additional 7,139 shares during the last quarter. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.